Xortx announces new clinical advisory board member

Calgary, alberta, march 27, 2024 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anua wkn: a3unz), a biopharmaceutical company focused on developing innovative therapies to treat autosomal dominant polycystic kidney disease (“adpkd”), is pleased to announce that dr. ronald perrone has joined the company's clinical advisory board.
XRTX Ratings Summary
XRTX Quant Ranking